Facebook
Twitter
Telegram
Report an ErrorNGM Biopharmaceuticals Balance Sheet 2011-2024 | NGM
Annual Balance Sheet NGM Biopharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -147 M | -246 M | -56.9 M | -25.6 M | -45.5 M | - | - | - | - | - |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | 5.38 M | 5.08 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 9.97 M | 17.7 M | 333 M | 354 M | - | - | - | - | - |
Total Current Liabilities |
20.1 M | 47.8 M | 61.4 M | 42.6 M | 39.7 M | - | - | - | - | - | - | - | - |
Total Liabilities |
20.2 M | 47.8 M | 66.7 M | 49 M | 49.7 M | 59.2 M | 370 M | 392 M | - | - | - | - | - |
Deferred Revenue |
- | 366 K | 17.8 M | - | 4.87 M | 19 M | 21.4 M | 19.1 M | - | - | - | - | - |
Retained Earnings |
-724 M | -582 M | -419 M | -299 M | -196 M | -147 M | -147 M | -133 M | - | - | - | - | - |
Total Assets |
169 M | 307 M | 402 M | 329 M | 380 M | 246 M | 249 M | 277 M | - | - | - | - | - |
Cash and Cash Equivalents |
55.8 M | 73.5 M | 153 M | 149 M | 246 M | 59.2 M | 27.8 M | - | - | - | - | - | - |
Book Value |
149 M | 260 M | 336 M | 280 M | 331 M | 187 M | -121 M | -115 M | - | - | - | - | - |
Total Shareholders Equity |
149 M | 260 M | 336 M | 280 M | 331 M | -108 M | -121 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet NGM Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 1.38 M | - | 4.07 M | 5.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
22.3 M | 28.4 M | 37.9 M | 47.8 M | 50 M | - | 48.6 M | 66.7 M | 61.8 M | 49.9 M | 46 M | 49 M | 49 M | 49 M | 49 M | 49.7 M | 49.7 M | 49.7 M | 49.7 M | 59.4 M | 59.4 M | 59.4 M | 59.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
107 K | 689 K | 376 K | 366 K | 6.97 M | - | 5.12 M | 17.8 M | 12.3 M | 4.96 M | - | - | - | - | - | 4.87 M | 4.87 M | 4.87 M | 4.87 M | 19 M | 19 M | 19 M | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-696 M | -668 M | -629 M | -582 M | -545 M | - | -451 M | -419 M | -392 M | -363 M | -326 M | -299 M | -299 M | -299 M | -299 M | -196 M | -196 M | -196 M | -196 M | -147 M | -147 M | -147 M | -147 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
192 M | 221 M | 259 M | 307 M | 336 M | - | 360 M | 402 M | 416 M | 423 M | 446 M | 329 M | 329 M | 329 M | 329 M | 380 M | 380 M | 380 M | 380 M | 246 M | 246 M | 246 M | 246 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
51.5 M | 53.3 M | 67.5 M | 73.5 M | 105 M | 64.9 M | 111 M | 152 M | 147 M | 99.4 M | 148 M | 147 M | 147 M | 147 M | 147 M | 246 M | 246 M | 246 M | 246 M | 56.9 M | 56.9 M | 56.9 M | 56.9 M | 25.6 M | - | - | - | 47.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
170 M | 192 M | 221 M | 260 M | 286 M | - | 311 M | 336 M | 354 M | 373 M | 400 M | 280 M | 280 M | 280 M | 280 M | 331 M | 331 M | 331 M | 331 M | 187 M | 187 M | 187 M | 187 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
170 M | 192 M | 221 M | 260 M | 286 M | 292 M | 311 M | 336 M | 354 M | 373 M | 400 M | 280 M | 280 M | 280 M | 280 M | 331 M | 331 M | 331 M | 331 M | -108 M | -108 M | -108 M | -108 M | -121 M | - | - | - | -115 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency